source
- Choosing the Right Radiopharmaceuticals for Advanced Prostate CancerDr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics affect the use of radiopharmaceuticals in metastatic castration‑resistant prostate cancer (mCRPC).…
- Experts review expanding role of radiopharmaceuticals in metastatic castration-resistant prostate cancerDr. Pedro Barata and Dr. Johann De Bono open a discussion on the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC). They describe how these agents ar…